Search - tctmd.com

Displaying 821 - 840 of 3616

Sort: Relevancy | Date

News Industry News

Stem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II Clinical Trial for Heart Failure

October 22, 2015

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

News Industry News

First Patient Enrolled in the SMILE Study, Sensible Medical Innovation's Randomized Controlled Trial (RCT) Designed to Measure ReDS™ Technology Impact on Heart Failure Rehospitalizations

October 20, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

Presentation TCT 2015

Disappointing Clinical Trial Experiences to Date: Should We Continue? In Which Setting? How?

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

Presenter: Somjot S. Brar, Richard Solomon, Roxana Mehran

October 15, 2015

Presentation TCT 2015

TCT 110: Up-to-1-Year Follow-up Results of the Transcatheter Annuloplasty Ring Multicentre Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Alec S. Vahanian

October 15, 2015

News Industry News

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

October 15, 2015

News Conference News TCT 2015

RESPECT Confirms Long-term Safety, Efficacy of PFO Closure for Recurrent Stroke

Nicole Lou

October 15, 2015

News Conference News TCT 2015

Low 1-Year Event Rates Seen After TAVR With Sapien 3

Todd Neale

October 15, 2015

News Industry News

Long-Term Study Results Show That PFO Closure May Be Effective In Preventing Recurrent Cryptogenic Stroke, Particularly In Younger Patients

October 15, 2015

News Industry News

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Presenter: Chuck Simonton, Gregg W. Stone

October 14, 2015

Advertisement

Stem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II Clinical Trial for Heart Failure

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

My Takeaways From TCT 2015

First Patient Enrolled in the SMILE Study, Sensible Medical Innovation's Randomized Controlled Trial (RCT) Designed to Measure ReDS™ Technology Impact on Heart Failure Rehospitalizations

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Disappointing Clinical Trial Experiences to Date: Should We Continue? In Which Setting? How?

Contrast Nephropathy Clinical Trial Updates (AVERT, RenalGuard, Preserve, and Others)

TCT 110: Up-to-1-Year Follow-up Results of the Transcatheter Annuloplasty Ring Multicentre Trial

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

RESPECT Confirms Long-term Safety, Efficacy of PFO Closure for Recurrent Stroke

Low 1-Year Event Rates Seen After TAVR With Sapien 3

Long-Term Study Results Show That PFO Closure May Be Effective In Preventing Recurrent Cryptogenic Stroke, Particularly In Younger Patients

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content